X4 Pharmaceuticals (XFOR) Stock Overview
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XFOR Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.64 |
| 52 Week High | US$4.83 |
| 52 Week Low | US$1.35 |
| Beta | 0.39 |
| 1 Month Change | 5.22% |
| 3 Month Change | 3.11% |
| 1 Year Change | 211.41% |
| 3 Year Change | -87.92% |
| 5 Year Change | -97.27% |
| Change since IPO | -98.98% |
Recent News & Updates
Narrative Update • Jun 17
XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential
Analysts have raised their 12 month price target on X4 Pharmaceuticals stock from $10 to $12, citing a more constructive view of the company’s lead program mavorixafor and its potential in the large, underpenetrated chronic neutropenia market. What’s in the News for X4 Pharmaceuticals X4 Pharmaceuticals received European Commission marketing authorization for XOLREMDI (mavorixafor) capsules to treat patients aged 12 and older with WHIM syndrome in the European Union, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
Narrative Update • Jun 03
XFOR: Chronic Neutropenia Opportunity Will Drive Future Upside Potential
Narrative Update on X4 Pharmaceuticals The consensus analyst price target for X4 Pharmaceuticals has moved to $12, with analysts pointing to the potential of lead drug mavorixafor in chronic neutropenia and WHIM syndrome as the main factor in their valuation analysis. Analyst Commentary Bullish analysts are highlighting X4 Pharmaceuticals as a focused rare disease story centered on mavorixafor, with both chronic neutropenia and WHIM syndrome at the core of their views.
Narrative Update • May 20
XFOR: Single Asset CXCR4 Platform Is Poised To Drive Upside
Analysts have lifted their price target on X4 Pharmaceuticals to $11.67 from $8.00, citing a stronger outlook for mavorixafor as a potential first in class oral CXCR4 antagonist in WHIM syndrome and primary chronic neutropenia. They note that the current valuation does not fully reflect its role as the company's key value driver.Recent updates
Narrative Update • Jun 17
XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential
Analysts have raised their 12 month price target on X4 Pharmaceuticals stock from $10 to $12, citing a more constructive view of the company’s lead program mavorixafor and its potential in the large, underpenetrated chronic neutropenia market. What’s in the News for X4 Pharmaceuticals X4 Pharmaceuticals received European Commission marketing authorization for XOLREMDI (mavorixafor) capsules to treat patients aged 12 and older with WHIM syndrome in the European Union, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.Narrative Update • Jun 03
XFOR: Chronic Neutropenia Opportunity Will Drive Future Upside Potential
Narrative Update on X4 Pharmaceuticals The consensus analyst price target for X4 Pharmaceuticals has moved to $12, with analysts pointing to the potential of lead drug mavorixafor in chronic neutropenia and WHIM syndrome as the main factor in their valuation analysis. Analyst Commentary Bullish analysts are highlighting X4 Pharmaceuticals as a focused rare disease story centered on mavorixafor, with both chronic neutropenia and WHIM syndrome at the core of their views.Narrative Update • May 20
XFOR: Single Asset CXCR4 Platform Is Poised To Drive Upside
Analysts have lifted their price target on X4 Pharmaceuticals to $11.67 from $8.00, citing a stronger outlook for mavorixafor as a potential first in class oral CXCR4 antagonist in WHIM syndrome and primary chronic neutropenia. They note that the current valuation does not fully reflect its role as the company's key value driver.Narrative Update • May 04
XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential
Analysts have raised their price target on X4 Pharmaceuticals to $12, citing what they view as significant upside potential from mavorixafor as a key value driver for WHIM syndrome and primary chronic neutropenia, along with a current valuation that they see as not fully reflecting this opportunity. Analyst Commentary Recent Street research frames X4 Pharmaceuticals as a focused hematology company, with attention centered on mavorixafor as a potential first in class oral CXCR4 antagonist for WHIM syndrome and primary chronic neutropenia.Narrative Update • Apr 20
XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside
Analysts have reset their price target on X4 Pharmaceuticals to $12, citing Guggenheim's recent initiation, which highlights mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary The latest Street research frames X4 Pharmaceuticals as closely tied to the success of mavorixafor in WHIM syndrome and primary chronic neutropenia.Narrative Update • Apr 05
XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential
Narrative Update Analysts have raised their price target for X4 Pharmaceuticals to $12, citing the perceived upside in mavorixafor as a key value driver and updating fair value assumptions to $10.00, along with adjusted growth, margin, discount rate, and future P/E inputs. Analyst Commentary Recent research points to mavorixafor as the central piece of the X4 Pharmaceuticals story, with coverage initiating at a $12 price target that aligns with the view of the drug as a key value driver.Narrative Update • Mar 22
XFOR: WHIM And Chronic Neutropenia Program Will Drive Future Upside
Analysts have adjusted their price target on X4 Pharmaceuticals to $12, noting what they view as potential upside tied to mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary Recent commentary from bullish analysts centers on how mavorixafor could reshape the risk reward profile for X4 Pharmaceuticals, especially as the program advances in WHIM syndrome and primary chronic neutropenia.Narrative Update • Mar 07
XFOR: EU WHIM Decision And Chronic Neutropenia Program Will Drive Upside Potential
Analysts have reset their price target for X4 Pharmaceuticals to $13.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that they see as better aligned with the company’s current risk and earnings profile. What's in the News The European Medicines Agency's CHMP adopted a positive opinion recommending marketing authorization, under exceptional circumstances, for mavorixafor to treat WHIM syndrome in the EU (Key Developments).Narrative Update • Feb 21
XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds
Analysts have lifted their fair value estimate for X4 Pharmaceuticals from $4.00 to $5.00 per share, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the new price target. Valuation Changes Fair Value was raised from $4.00 to $5.00 per share, an increase of 25% in the modelled estimate.Narrative Update • Feb 06
XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones
Analysts have lifted their price target on X4 Pharmaceuticals to $4.00 per share from $4.00, citing updated assumptions around revenue growth, discount rate, profit margin, and future P/E that are now reflected in their models. Valuation Changes Fair Value: Maintained at $4.00 per share, with no change from the prior estimate.Narrative Update • Jan 23
XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones
Narrative Update Analysts have trimmed their 12 month price target on X4 Pharmaceuticals to US$7.50 from US$9.00, mainly reflecting updated financing assumptions after the recent earnings report and the October capital raise. Analyst Commentary Bearish analysts are using the latest earnings report and the October capital raise to reset expectations on X4 Pharmaceuticals, with the 12 month price target update to US$7.50 at the center of their view.Narrative Update • Jan 09
XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones
Analysts have trimmed their 12 month price target for X4 Pharmaceuticals to US$7.50 from US$9.00, citing updated financing assumptions following the October capital raise as well as recent earnings and corporate updates. Analyst Commentary Bearish analysts are framing the lower US$7.50 12 month price target as a reset that reflects updated expectations after recent earnings and the October capital raise.Analysis Article • Dec 24
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon
With a median price-to-sales (or "P/S") ratio of close to 12.4x in the Biotechs industry in the United States, you...Narrative Update • Dec 22
XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside
Analysts have trimmed their price target on X4 Pharmaceuticals by $1.50 to $7.50, citing updated models that factor in revised financing assumptions following the company’s recent earnings report and October capital raise. Analyst Commentary Bearish analysts have pointed to the latest target cut as evidence that X4 Pharmaceuticals faces a more challenging path to value creation than previously modeled, with revised financing assumptions weighing on upside potential.Narrative Update • Dec 07
XFOR: Recent Financing Will Support Key Phase 3 Progress And Upside Potential
Analysts have modestly trimmed their fair value estimate for X4 Pharmaceuticals, cutting the price target from $9.00 to $7.50, as updated models incorporate revised financing assumptions following the company's recent capital raise. Analyst Commentary Analyst updates following the latest earnings report and corporate update emphasize that the lower price target is primarily a function of revised financing assumptions rather than a fundamental shift in the long term outlook for X4 Pharmaceuticals.Narrative Update • Nov 23
XFOR: Leadership Overhaul And Fresh Capital Will Drive Pipeline Progress
Analysts have revised their price target for X4 Pharmaceuticals downward from $8.70 to $7.38. They cite updated financing assumptions and recent corporate developments as key factors behind the adjustment.Narrative Update • Sep 25
US Launch And EMA Approval Will Expand Global Reach
Amid leadership changes and a recapitalization that add near-term execution risk despite long-term potential for mavorixafor in a substantial unmet market, analysts have lowered their price target for X4 Pharmaceuticals from $19.75 to $8.70. Analyst Commentary Leadership overhaul and new senior management introduce execution uncertainty but may improve strategic direction.Narrative Update • Sep 02
US Launch And EMA Approval Will Expand Global Reach
Analysts have lowered their price target for X4 Pharmaceuticals from $23.25 to $19.75, citing increased execution risks and near-term uncertainty from a leadership overhaul, tempered by optimism over recent recapitalization and the long-term potential of mavorixafor. Analyst Commentary Recent complete overhaul of the senior leadership team introduces uncertainty but also the potential for strategic renewal.Narrative Update • Aug 19
US Launch And EMA Approval Will Expand Global Reach
A significant reduction in X4 Pharmaceuticals’ future P/E signals lower growth expectations or improved earnings outlook, while a decreased discount rate indicates lower perceived risk, contributing to a sharp downward revision in the fair value estimate from $41.08 to $23.25. What's in the News X4 Pharmaceuticals completed a private placement, issuing 11,040,776 shares at $1.42 and 48,852,772 pre-funded warrants at $1.419, raising $85 million, led by Coastlands Capital LP and supported by top life science investors.Analysis Article • Aug 12
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors
You may think that with a price-to-sales (or "P/S") ratio of 0.3x X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) is...
New Narrative • Mar 30
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.Seeking Alpha • Jul 02
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Summary X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration. I discuss why I am attempting to "catch the falling knife." Read the full article on Seeking AlphaAnalysis Article • Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Shareholder Returns
| XFOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.6% | 6.3% | 4.2% |
| 1Y | 211.4% | 40.9% | 20.6% |
Return vs Industry: XFOR exceeded the US Biotechs industry which returned 40.9% over the past year.
Return vs Market: XFOR exceeded the US Market which returned 20.6% over the past year.
Price Volatility
| XFOR volatility | |
|---|---|
| XFOR Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XFOR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XFOR's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 45 | n/a | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| XFOR fundamental statistics | |
|---|---|
| Market cap | US$437.64m |
| Earnings (TTM) | -US$90.14m |
| Revenue (TTM) | US$15.85m |
27.6x
P/S Ratio-4.9x
P/E RatioIs XFOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XFOR income statement (TTM) | |
|---|---|
| Revenue | US$15.85m |
| Cost of Revenue | US$2.93m |
| Gross Profit | US$12.92m |
| Other Expenses | US$103.06m |
| Earnings | -US$90.14m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 81.51% |
| Net Profit Margin | -568.80% |
| Debt/Equity Ratio | 49.4% |
How did XFOR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 06:47 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Michael Schmidt | Guggenheim Securities, LLC |